Clinical trial
Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With…
NCT00051987 · Millennium Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00051987 |
|---|---|
| Title | Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma |
| Official title | A Randomized, Multicenter, Open-Label, Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma |
| Lead sponsor | Millennium Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Carcinoma |
| Intervention type | Drug |
| Interventions | VELCADE TM (bortezomib) for Injection, or PS-341 |
| Enrollment | 175 |
| Start date | Dec 1, 2002 |
| Primary completion | Mar 1, 2004 |
| First posted | Jan 22, 2003 |
| Last update posted | Feb 11, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: